TumourTrack - Comprehensive Tumor Panel (SNVs, Indels, CNVs and Fusions)

MedGenome's Comprehensive Tumor Panel is a cutting-edge, high-throughput next-generation sequencing assay designed to unearth critical genomic aberrations responsible for cancer development. This comprehensive panel goes beyond conventional testing, as it encompasses a wide range of alterations, including single nucleotide variants (SNVs), insertions and deletions (InDels), copy number variations (CNVs), and gene fusions. By doing so, it equips oncologists with a holistic view of a patient's tumor, facilitating tailored treatment strategies.

The panel comprises a multitude of cancer-related genes of over 324 genes, aligning with the NCCN guidelines, and exhaustively reports both known and novel fusion gene partners. Furthermore, genes implicated in the Homologous Recombination Repair (HRR) pathway are included, offering a comprehensive assessment of potential therapeutic targets. MedGenome's Comprehensive Tumor Panel offers a comprehensive genetic roadmap for oncologists, enabling tailored therapeutic decisions based on a thorough understanding of a patient's tumor biology.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.